Reaction

Radiotherapy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,890 reports · 40 co-occurring drugs

As of the last recalculation, Radiotherapy appears in 1,890 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 45.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pembrolizumab	352	45.0	45.2
Sitagliptin And Metformin Hydrochloride	39	20.3	20.3
Octreotide Acetate	51	18.8	18.8
Pemetrexed	35	18.3	18.3
Conjugated Estrogens And Medroxyprogesterone Acetate	37	17.6	17.6
Sitagliptin	103	16.6	16.6
Rucaparib	11	13.8	13.8
Trifluridine And Tipiracil	13	13.4	13.4
Carboplatin	132	12.2	12.2
Cabozantinib	52	12.2	12.2
Diphenoxylate Hydrochloride And Atropine Sulfate	15	12.1	12.2
Pemetrexed Disodium	41	12.1	12.1
Abiraterone Acetate	43	11.8	11.8
Paclitaxel (Aibumin-Bound)	78	10.9	10.9
Apalutamide	11	10.4	10.4
Lanreotide Acetate	7	9.9	9.9
Pancrelipase	33	9.6	9.6
Bicalutamide	13	9.5	9.5
Medroxyprogesterone Acetate	41	9.2	9.2
Paclitaxel	78	9.0	9.0
Pazopanib Hydrochloride	19	7.8	7.8
Avapritinib	8	7.3	7.3
Conjugated Estrogens	37	7.1	7.1
Estrogens, Conjugated	37	7.0	7.0
Leuprolide Acetate	48	7.0	7.0
Lapatinib	9	6.4	6.4
Abiraterone	7	5.7	5.7
Exenatide	26	5.5	5.5
Pegfilgrastim	47	5.4	5.4
Fluticasone Propionate And Salmeterol	20	5.3	5.3
Umeclidinium Bromide And Vilanterol Trifenatate	8	5.3	5.3
Selinexor	4	5.1	5.1
Bosentan	23	5.1	5.1
Brivaracetam	4	4.9	4.9
Olaparib	9	4.8	4.8
Panitumumab	6	4.2	4.2
Ranolazine	4	4.2	4.2
Relugolix	9	4.2	4.2
Axitinib	7	4.0	4.0
Pimavanserin Tartrate	6	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.